The Dutch Competition Authority closes investigation into drug manufacturer after receiving assurances that it will not use its discount schemes to force hospitals into exclusive purchases (AbbVie)

ACM closes investigation into drug manufacturer AbbVie, competitors get more room now* Drug manufacturer AbbVie has stated that it will not force hospitals to purchase exclusively or to a large extent from AbbVie through discount schemes (or rebate programs). AbbVie has made these assurances following an investigation conducted by the Netherlands Authority for Consumers and Markets (ACM). This ensures that, once a patent has expired, there will be more room for new competing drugs (biosimilars). With these assurances with regard to AbbVie’s discount policy in tender processes, ACM has closed its investigation into anti-rheumatic drug Humira, and into possible abuse of a dominant position by AbbVie. Martijn Snoep, Chairman of the Board of ACM: “In general, competition should be freely

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Dutch Competition Authority, The Dutch Competition Authority closes investigation into drug manufacturer after receiving assurances that it will not use its discount schemes to force hospitals into exclusive purchases (AbbVie), 24 September 2020, e-Competitions September 2020, Art. N° 96990

Visites 210

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues